Lin BioScience, Inc.
6696
Rangering i aksjer
#3772
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aksjekurs
$5.34
Markedsverdi
$4.43B
Endring (1 dag)
3.07%
Endring (1 år)
-39.48%
Land
TW
Handel Lin BioScience, Inc. (6696)
Kategori
Healthcare
Historikk for aksjesplitt for Lin BioScience, Inc. (6696)
Aksjen Lin BioScience, Inc. (symbol: 6696) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én 6696-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 6696-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én 6696-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 6696-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
